Skip to main content
Fig. 5 | BMC Medical Genomics

Fig. 5

From: Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma

Fig. 5

ARS was a robust biomarker for the RFS of early-stage LUAD patients. A–E The predictive performance of ARS in the TCGA cohort (A), GSE30219 cohort (B), GSE31210 cohort (C), GSE37745 cohort (D), and GSE50081 cohort (E). F The meta-analysis indicated that the early-stage LUAD patients with high ARS suffered poorer RFS. LUAD lung adenocarcinoma, RFS recurrence-free survival, ARS acetylation-related score, TCGA the Cancer Genome Atlas

Back to article page